PDCD1 and hepatocellular carcinoma: In CheckMate-459, a multicenter phase 3 trial, 743 patients with advanced HCC were randomized to receive nivolumab, a PD1-inhibitor or sorafenib, a tyrosine kinase VEGF inhibitor, as a first-line treatment.